The effect of autophagy-enhancing peptide in moisturizer on atopic dermatitis

a randomized controlled trial

Soon Hyo Kwon, Chae Jin Lim, Juyeon Jung, Heung Jae Kim, Keedon Park, Jung Won Shin, Chang Hun Huh, Kyungchan Park, Jung Im Na

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Pentasodium tetracarboxymethyl palmitoyl dipeptide-12 (PTPD-12), a newly-synthesized peptide, enhances the autophagy activity, ultimately managing inflammation. Objective: To determine the effect of a new moisturizer containing PTPD-12 as the treatment of mild-to-moderate atopic dermatitis (AD). Methods: In this double-blind, randomized, placebo-controlled trial, 43 patients with mild-to-moderate AD were randomly assigned to either the PTPD-12 or control groups. Evaluations were performed at baseline, week 2, and week 4, including SCORing Atopic Dermatitis (SCORAD) index score, corneometry, trans-epidermal water loss (TEWL), visual analog scale (VAS) for pruritus, 7-point investigator’s global assessment (IGA), and collection of adverse events. Results: The PTPD-12 group showed significant improvement with respect to SCORAD score, skin hydration, TEWL, and pruritus at weeks 2 and 4 when compared with baseline. Although the control group showed significant improvement regarding the SCORAD score and skin hydration, no significant change in TEWL or pruritus was demonstrated throughout the study. The mean changes in the SCORAD index score, skin hydration, TEWL, pruritus, and number of patients with improvement in IGA were not statistically different between the two groups. Conclusion: The moisturizer with autophagy-stimulating property provides a good therapeutic option to mild-to-moderate atopic dermatitis by contributing to skin barrier restoration and control of inflammation.

Original languageEnglish
Pages (from-to)558-564
Number of pages7
JournalJournal of Dermatological Treatment
Volume30
Issue number6
DOIs
StatePublished - 18 Aug 2019

Fingerprint

Autophagy
Atopic Dermatitis
Randomized Controlled Trials
Dipeptides
Peptides
Pruritus
Skin
Water
Research Personnel
Inflammation
Control Groups
Visual Analog Scale
Double-Blind Method
Placebos
Therapeutics

Keywords

  • Atopic dermatitis
  • autophagy
  • moisturizer
  • pentasodium tetracarboxymethyl palmitoyl dipeptide-12

Cite this

Kwon, Soon Hyo ; Lim, Chae Jin ; Jung, Juyeon ; Kim, Heung Jae ; Park, Keedon ; Shin, Jung Won ; Huh, Chang Hun ; Park, Kyungchan ; Na, Jung Im. / The effect of autophagy-enhancing peptide in moisturizer on atopic dermatitis : a randomized controlled trial. In: Journal of Dermatological Treatment. 2019 ; Vol. 30, No. 6. pp. 558-564.
@article{b090caff9529485ba3395fa02fe6e89a,
title = "The effect of autophagy-enhancing peptide in moisturizer on atopic dermatitis: a randomized controlled trial",
abstract = "Background: Pentasodium tetracarboxymethyl palmitoyl dipeptide-12 (PTPD-12), a newly-synthesized peptide, enhances the autophagy activity, ultimately managing inflammation. Objective: To determine the effect of a new moisturizer containing PTPD-12 as the treatment of mild-to-moderate atopic dermatitis (AD). Methods: In this double-blind, randomized, placebo-controlled trial, 43 patients with mild-to-moderate AD were randomly assigned to either the PTPD-12 or control groups. Evaluations were performed at baseline, week 2, and week 4, including SCORing Atopic Dermatitis (SCORAD) index score, corneometry, trans-epidermal water loss (TEWL), visual analog scale (VAS) for pruritus, 7-point investigator’s global assessment (IGA), and collection of adverse events. Results: The PTPD-12 group showed significant improvement with respect to SCORAD score, skin hydration, TEWL, and pruritus at weeks 2 and 4 when compared with baseline. Although the control group showed significant improvement regarding the SCORAD score and skin hydration, no significant change in TEWL or pruritus was demonstrated throughout the study. The mean changes in the SCORAD index score, skin hydration, TEWL, pruritus, and number of patients with improvement in IGA were not statistically different between the two groups. Conclusion: The moisturizer with autophagy-stimulating property provides a good therapeutic option to mild-to-moderate atopic dermatitis by contributing to skin barrier restoration and control of inflammation.",
keywords = "Atopic dermatitis, autophagy, moisturizer, pentasodium tetracarboxymethyl palmitoyl dipeptide-12",
author = "Kwon, {Soon Hyo} and Lim, {Chae Jin} and Juyeon Jung and Kim, {Heung Jae} and Keedon Park and Shin, {Jung Won} and Huh, {Chang Hun} and Kyungchan Park and Na, {Jung Im}",
year = "2019",
month = "8",
day = "18",
doi = "10.1080/09546634.2018.1544407",
language = "English",
volume = "30",
pages = "558--564",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "6",

}

The effect of autophagy-enhancing peptide in moisturizer on atopic dermatitis : a randomized controlled trial. / Kwon, Soon Hyo; Lim, Chae Jin; Jung, Juyeon; Kim, Heung Jae; Park, Keedon; Shin, Jung Won; Huh, Chang Hun; Park, Kyungchan; Na, Jung Im.

In: Journal of Dermatological Treatment, Vol. 30, No. 6, 18.08.2019, p. 558-564.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The effect of autophagy-enhancing peptide in moisturizer on atopic dermatitis

T2 - a randomized controlled trial

AU - Kwon, Soon Hyo

AU - Lim, Chae Jin

AU - Jung, Juyeon

AU - Kim, Heung Jae

AU - Park, Keedon

AU - Shin, Jung Won

AU - Huh, Chang Hun

AU - Park, Kyungchan

AU - Na, Jung Im

PY - 2019/8/18

Y1 - 2019/8/18

N2 - Background: Pentasodium tetracarboxymethyl palmitoyl dipeptide-12 (PTPD-12), a newly-synthesized peptide, enhances the autophagy activity, ultimately managing inflammation. Objective: To determine the effect of a new moisturizer containing PTPD-12 as the treatment of mild-to-moderate atopic dermatitis (AD). Methods: In this double-blind, randomized, placebo-controlled trial, 43 patients with mild-to-moderate AD were randomly assigned to either the PTPD-12 or control groups. Evaluations were performed at baseline, week 2, and week 4, including SCORing Atopic Dermatitis (SCORAD) index score, corneometry, trans-epidermal water loss (TEWL), visual analog scale (VAS) for pruritus, 7-point investigator’s global assessment (IGA), and collection of adverse events. Results: The PTPD-12 group showed significant improvement with respect to SCORAD score, skin hydration, TEWL, and pruritus at weeks 2 and 4 when compared with baseline. Although the control group showed significant improvement regarding the SCORAD score and skin hydration, no significant change in TEWL or pruritus was demonstrated throughout the study. The mean changes in the SCORAD index score, skin hydration, TEWL, pruritus, and number of patients with improvement in IGA were not statistically different between the two groups. Conclusion: The moisturizer with autophagy-stimulating property provides a good therapeutic option to mild-to-moderate atopic dermatitis by contributing to skin barrier restoration and control of inflammation.

AB - Background: Pentasodium tetracarboxymethyl palmitoyl dipeptide-12 (PTPD-12), a newly-synthesized peptide, enhances the autophagy activity, ultimately managing inflammation. Objective: To determine the effect of a new moisturizer containing PTPD-12 as the treatment of mild-to-moderate atopic dermatitis (AD). Methods: In this double-blind, randomized, placebo-controlled trial, 43 patients with mild-to-moderate AD were randomly assigned to either the PTPD-12 or control groups. Evaluations were performed at baseline, week 2, and week 4, including SCORing Atopic Dermatitis (SCORAD) index score, corneometry, trans-epidermal water loss (TEWL), visual analog scale (VAS) for pruritus, 7-point investigator’s global assessment (IGA), and collection of adverse events. Results: The PTPD-12 group showed significant improvement with respect to SCORAD score, skin hydration, TEWL, and pruritus at weeks 2 and 4 when compared with baseline. Although the control group showed significant improvement regarding the SCORAD score and skin hydration, no significant change in TEWL or pruritus was demonstrated throughout the study. The mean changes in the SCORAD index score, skin hydration, TEWL, pruritus, and number of patients with improvement in IGA were not statistically different between the two groups. Conclusion: The moisturizer with autophagy-stimulating property provides a good therapeutic option to mild-to-moderate atopic dermatitis by contributing to skin barrier restoration and control of inflammation.

KW - Atopic dermatitis

KW - autophagy

KW - moisturizer

KW - pentasodium tetracarboxymethyl palmitoyl dipeptide-12

UR - http://www.scopus.com/inward/record.url?scp=85058129760&partnerID=8YFLogxK

U2 - 10.1080/09546634.2018.1544407

DO - 10.1080/09546634.2018.1544407

M3 - Article

VL - 30

SP - 558

EP - 564

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 6

ER -